41263-65-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-3-nitrobenzamide is used as an intermediate in the production of various pharmaceuticals for its ability to be incorporated into the molecular structures of different drugs, enhancing their therapeutic properties.
Used in Dye Industry:
In the dye industry, 4-Amino-3-nitrobenzamide is used as a chemical intermediate for synthesizing dyes, contributing to the development of colorants for various applications.
Used in Organic Synthesis:
4-Amino-3-nitrobenzamide serves as a building block in organic synthesis, allowing for the creation of complex organic compounds that can be utilized in a wide range of industries.
Safety Precautions:
Due to its toxic nature if ingested or inhaled, 4-amino-3-nitrobenzamide should be handled with care. It is essential to use proper protective equipment when working with this chemical to minimize potential health hazards.

Upstream product

• 400-94-2 4-fluoro-3-nitrobenzoyl chloride 
• 24376-18-9 3,4-dinitrobenzoyl chloride 
• 879-93-6 4-bromo-3-nitrobenzamide 
• 1588-83-6 4-amino-3-nitrobenzoic acid 
• 937625-32-6 ethyl 4-ethoxy-3-nitrobenzoate 
• 76918-64-4 ethyl 4-amino-3-nitrobenzoate 

Downstream Products

• 7005-37-0 3,4-diamino-benzamide 
• 1028903-37-8 2-[4-(3-methoxyphenoxy)phenyl]-1H-benzimidazole-5-carboxylic acid amide 
• 1186126-07-7 C₁₅H₁₇N₃O₄ 
• 516481-11-1 2-[4-(3-carboxy-phenoxy)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide 

Relevant academic research and scientific papers

STING AGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the modulation of STING, and the treatment of STING-mediated disorders.

Benzimidazole inhibitors of the protein kinase CHK2: Clarification of the binding mode by flexible side chain docking and protein-ligand crystallography

Two closely related binding modes have previously been proposed for the ATP-competitive benzimidazole class of checkpoint kinase 2 (CHK2) inhibitors; however, neither binding mode is entirely consistent with the reported SAR. Unconstrained rigid docking o

Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles

The discovery of a series of novel, potent, and highly selective inhibitors of the DNA damage control kinase chk2 is disclosed. Here we report the first SAR study around inhibitors of this kinase. High-throughput screening of purified human chk2 led to the identification of a novel series of 2-arylbenzimidazole inhibitors of the kinase. Optimization was facilitated using homology models of chk2 and docking of inhibitors, leading to the highly potent 2-arylbenz-imidazole 2h (IC50 15 nM). Compound 2h is an ATP-competitive inhibitor of chk2 that dose dependency protects human CD4 + and CD8+ T-cells from apoptosis due to ionizing radiation. This work suggests that a selective small molecule inhibitor of chk2 could be a useful adjuvant to radiotherapy, increasing the therapeutic window of such treatment.